SCHEMBL634522

SCHEMBL634522

Cc1cccc(Nc2nc(Cl)ncc2Cl)c1NS(C)(=O)=O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 5/20 0.44
MET P08581 1/20 0.43
CCNA2 P20248 3/20 0.43
CDK2 P24941 3/20 0.43
CDK9 P50750 3/20 0.43
CCNK O75909 2/20 0.43
CCND3 P30281 2/20 0.43
CDK6 Q00534 2/20 0.43
LRRK2 Q5S007 1/20 0.41
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
EGFR P00533 2/20 0.41
PTK2 Q05397 1/20 0.41
PIN1 Q13526 1/20 0.39
ROS1 P08922 1/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
GLO1 Q04760 1/20 0.39
CDK7 P50613 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31147617 1.00 ALK (0.44) ALKMETCCNA2CDK2CDK9
SCHEMBL30942662 0.90 ALK (0.46) ALKMETCDK9LRRK2EGFR
SCHEMBL603145 0.88 GLO1 (0.52) LRRK2KEAP1NFE2L2PTK2PIN1
SCHEMBL25004226 0.86 ALK (0.44) ALKMETCDK9LRRK2EGFR
SCHEMBL31147671 0.86 ALK (0.44) ALKMETCDK9LRRK2EGFR
SCHEMBL27238042 0.85 ALK (0.39) ALKMETCCNA2CDK2CDK9
SCHEMBL542158 0.83 ALK (0.54) ALKMETLRRK2EGFRPIN1
SCHEMBL29435445 0.83 ALK (0.54) ALKMETLRRK2EGFRPIN1
SCHEMBL31147673 0.81 LCK (0.46) ALKCCNA2CDK2CDK9CCNK
SCHEMBL25005393 0.81 LCK (0.46) ALKCCNA2CDK2CDK9CCNK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4382514-A1 PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT Korea Research Institute of Chemical Technology (KR) 2024-06-12 EP disclosed
EP-2419423-A1 FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS Cellzome Limited (GB) 2012-02-22 EP disclosed
US-20120040955-A1 FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS CELLZOME LIMITED (GB) 2012-02-16 US disclosed
US-20120040955-A1 FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS CELLZOME LIMITED (GB) 2012-02-16 US disclosed
WO-2010118986-A1 FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS CELLZOME LIMITED (GB) 2010-10-21 WO disclosed
WO-2010118986-A1 FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS CELLZOME LIMITED (GB) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040955-A1 FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS JAK3, JAK2, JAK1 ALK 1095/4885MET 3143/4885CCNA2 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.